
    
      This regional multi-center study is planned to be carried out in Guangdong and Sichuan
      provinces. 48 cases are preliminarily expected to be included. The study will start in
      January 2019 and end in December 2019. It is expected that the trial will end in December
      2020. This study evaluating the safety and efficacy of anlotinib as a maintenance treatment
      in advanced soft tissue sarcoma.

      All those participants need to sign informed consent forms for data collection and be used
      for research purpose before inclusion. Participants remained PR/SD after â‰¥4 cycles of
      anthracyclines could be enrolled.

      48 subjects with advanced soft tissue sarcoma will receive anlotinib at a dose of 12 mg once
      daily (day1-14 PO) in 21-day cycles until disease progression (defined by RECIST version 1.1)
      or unacceptable toxicity.
    
  